Our Global Focus

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B virus and age-related diseases. Leveraging our expertise in structure-based drug design and our innovative drug discovery engine, we have developed a robust pipeline of eight drug candidates that disrupt complex and difficult-to-target protein-protein interactions (PPIs), and next-generation tyrosine kinase inhibitors (TKIs). Our PPI drug candidates are designed to treat cancer and other diseases by restoring the normal function of key apoptotic pathways, including the Bcl-2/Bcl-xL, MDM2-p53 and IAP pathways, which play a pivotal role in regulating apoptosis. We are also developing next-generation TKIs to treat diseases for high unmet medical needs. Our compounds are being developed for use as a single agent or in combination with other therapies.

 

Our founders have been dedicated to apoptosis-targeted drug innovation for over two decades

 

Mission, Vision and Values

Our Mission

Our Mission

To pioneer a new class of medicines that can address the most difficult-to-treat diseases – and improve the lives of patients in China and globally

Our Vision

Our Vision

To become a world-leading, science-driven biophar-maceutical company

Our Values

Our Values

Patients First

Innovation-Driven

Science-Based

 

Founded in 2009, our Group is headquartered in Suzhou, China

Founded in 2010, Ascentage Pharma is headquartered in Suzhou, China
Founded in 2010, Ascentage Pharma is headquartered in Suzhou, China